Profile: Diapulse Corporation of America provides biophysical therapeutic effects of non-thermal pulsed electromagnetic energy in medicine. We manufacture and develop the proprietary Diapulse® medical technology. The Diapulse is a pulsed non-thermal electromagnetic therapy, and it is indicated for the adjunctive use in the palliative treatment of postoperative edema and pain in superficial soft tissues, in acute & chronic wounds. The Diapulse is medicare covered to treat Stage III and IV pressure ulcers, venous stasis ulcers, arterial ulcers & diabetic ulcers in hospitals, nursing homes and therapy clinics.

The company was founded in 1957, has revenues of USD 1-5 Million, has ~40 employees. OTC:DIAC (SEC Filings)